The risk of nephrocalcinosis in preterm infants is considerable, but conflicting numbers are given for the actual incidence (10-65%). Furosemide induced hypercalciuria is said to be the main risk factor. We examined retrospectively the incidence, causes and outcome of nephrocalcinosis in preterm infants born in our hospital from 1988 to 1998 ( n=2190). An abnormal renal echogenicity or nephrocalcinosis was seen in 31 infants (29.7+/-3.3 weeks gestational age; 1307+/-690 g birth weight). Nephrocalcinosis was diagnosed in 16, hyperechoic kidneys (HK) in 10 and Tamm-Horsfall kidneys in 5 infants. Main risk factors were low gestation age and birth weight, length of hospitalization, variations in acid-base status, length of assistant ventilation and hypercalciuria at diagnosis. The incidence of nephrocalcinosis was 0.73% [1.7% for low birth weight infants (VLBW)]. Taking the cases of nephrocalcinosis and HK together, incidence was calculated to be 1.2% overall and 2.5% for VLBW infants, but increased to 7% in 1998. The follow-up showed persisting nephrocalcinosis or hyperechoic kidneys in 8/26 preterm infants. In conclusion, the incidence of nephrocalcinosis was lower in our population than is usually reported. The numbers have, however, increased over the past few years. From the follow-up it was obvious that long-term observation of preterm infants is necessary and that complications might arise in the long run.

No abstract

Oxalate elimination and oxalate dialysance via hemodialysis (HD) or peritoneal dialysis (CAPD) has not been studied in detail in pediatric patients. We studied plasma oxalate, oxalate elimination, and oxalate dialysance in 15 infants and children undergoing CAPD (9 female, 6 male, aged 9 months to 18 years) and in 10 children on HD (4 female, 6 male, aged 7-18 years). Two children in each group had primary hyperoxaluria (PH). The mean duration of dialysis prior to examination was 12 +/- 11 months in CAPD and 31 +/- 23 months in HD patients. Bicarbonate HD was performed 5 h three times a week, CAPD consisted of five daily exchanges in 5 patients and four changes in the remaining 10 children (dwell volume 40 ml/kg body weight, 2.3 g/l glucose). Although oxalate dialysance was significantly higher in HD (mean 115.6 ml/ min per 1.73 m2 in HD versus 7.14 ml/min in CAPD), mean oxalate elimination per week was not different between both renal replacement therapies (3,478 mumol/1.73 m2 surface area/week in CAPD versus 3,915 mumol/1.73 m2 per week in HD). Oxalate elimination in patients with PH was between 6,650 and 9,900 mumol/week. Plasma oxalate remained elevated in both procedures [28-84 mumol/l in CAPD (92/148 in PH) and 33-101 mumol/l in HD (70/93 in PH)]. Oxalate elimination can be increased by a more frequent hemodialysis regimen.

In connection with the prevention of osteoporosis, paediatrics is challenged with ensuring the optimal formation of the skeletal system with maximal bone strength during childhood and youth. Biomechanical use represents the most important stimulus for activating the skeletal system. The measurement of muscle strength (grip strength) in 97 females aged 3-62 years and 71 males aged 3-61 years showed an age-dependent course. On the whole, males have greater strength with a more pronounced increase after puberty, reaching a peak maximum at 25-30 years. Females show a more moderate increase after puberty. In a pilot study, bone strength (as bone strength index – BSI) was analysed at the distal radius using peripheral quantitative computerized tomography (pQCT). BSI was calculated on the basis of the geometric data of the polar moment of resistance in combination with the cortical bone density. BSI values increase with age and reach a peak maximum at 25-30 years. There was a highly significant correlation between BSI and grip strength (r = 0.87). These relationships are especially interesting for therapeutic concepts differentiating between direct and indirect (via the muscle system) influences on the skeletal system. The non-invasive bone strength analysis in combination with muscle strength offer new perspectives for the evaluation of the functional muscle-bone unit.

These results suggest that MMF is safe and beneficial as a longer term maintenance immunosuppressive drug in children and adolescents.